A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
Authors:
Open Access
- 1 November 1993
- journal article
- Published by American Society of Hematology in Blood
- Vol. 82 (9) , 2624-2633
Abstract
Twenty-six patients, whose B-cell lymphoma had relapsed after conventional therapies, were treated in a phase I dose escalation study with an immunotoxin consisting of a mouse CD22 monoclonal antibody (RFB4:IgG1K) coupled to chemically deglycosylated ricin A chain (dgA). Two to 12 doses of the immunotoxin were infused intravenously at 48- hour intervals. The peak serum concentration and half-life (T1/2) did not correlate directly with the dose and averaged 3.8 micrograms/mL and 7.8 hours, respectively. The main dose-limiting toxicity was caused by the vascular leak syndrome (VLS) consisting of weight gain, edema, serum albumin decrease, and critically by pulmonary edema. Myalgia occurred frequently and was only dose limiting in one patient who developed rhabdomyolysis. The presence of lymphoma cells in the blood (> or = 10(10)/L) and clinically detectable splenomegaly were associated with reduced toxicity and a shorter T1/2. Nine of 24 evaluable patients (37.5%) made antibody to either mouse Ig or dgA. There were five partial responses (PR) and one complete response (CR) lasting 30 to 78 days. High peak concentrations of immunotoxin in the serum, a long T1/2, and large areas under the curve (AUC) correlated with both clinical response and toxicity. None of three patients with CD5+ lymphomas (including two CLL patients) had more than mild toxicity or responded to the immunotoxin.Keywords
This publication has 6 references indexed in Scilit:
- Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxinThe Lancet, 1992
- Immunotoxins: a clinical review of their use in the treatment of malignancies.Journal of Clinical Oncology, 1989
- Factors Predicting Survival in Adults with Stage I and II Large-Cell Lymphoma Treated with Primary Radiation TherapyAnnals of Internal Medicine, 1986
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- A comparison of the accumulation of ricin by hepatic parenchymal and non-parenchymal cells and its inhibition of protein synthesisBiochimica et Biophysica Acta (BBA) - General Subjects, 1981
- Changes in the surface membrane of lymphocytes from patients with chronic lymphocytic leukemia and hodgkin's diseaseInternational Journal of Cancer, 1975